Bristol Myers Squibb’s upcoming readout for its fibrosis candidate admilparant faces renewed scrutiny after the company disclosed a limited number of liver-related safety events, including a patient death, in a May amendment. A spokesperson confirmed that the events were observed in testing, though the disclosure did not establish whether the drug caused the injury. The update arrives as biotech developers in fibrosis continue to raise bar on liver safety monitoring and endpoint interpretation. For investors and clinicians, the key uncertainty is whether the safety signals alter confidence in the benefit-risk balance for registrational-grade evidence. The development also points to the practical impact of late-cycle protocol amendments and how rapidly disclosed adverse events can reshape expectations ahead of major data releases.